A ternary outcome for Tocagen
Tocagen’s Toca-5 trial has survived two interim reviews, and faces final readout by the end of this year.
Hard knocks for brain cancer, again
In the wake of two phase III glioblastoma failures this month, from Abbvie and Bristol-Myers Squibb, hopes dim for another big readout from Tocagen.
Wrong to try?
Will US right-to-try legislation be a means of giving hope to terminally ill patients, or drug another way for drug regulatory standards to fall?
